Published in Cochrane Database Syst Rev on June 30, 2015
Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients. Drug Des Devel Ther (2016) 0.75
Making anticoagulation easier and safer in DVT. Cochrane Database Syst Rev (2015) 0.75
Risk impact of edoxaban in the management of stroke and venous thromboembolism. Vasc Health Risk Manag (2016) 0.75
Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies. Drug Saf (2016) 0.75
Pathways for outpatient management of venous thromboembolism in a UK centre. Thromb J (2016) 0.75
Review: DOACs do not differ from standard anticoagulants for recurrent VTE; factor Xa inhibitors reduce bleeding. Ann Intern Med (2015) 0.75
A randomized trial of genotype-guided dosing of warfarin. N Engl J Med (2013) 7.18
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood (2005) 4.91
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. Cochrane Database Syst Rev (2015) 1.39
The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol (2004) 1.31
Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther (2004) 1.31
QT prolongation in patients with Type 2 diabetes and microalbuminuria. Clin Auton Res (2002) 1.13
Venous thromboembolism in patients with primary bone or soft-tissue sarcomas. J Bone Joint Surg Am (2007) 1.02
Comparison of D-dimer point of care test (POCT) against current laboratory test in patients with suspected venous thromboembolism (VTE) presenting to the emergency department (ED). J Clin Pathol (2013) 0.83
Platelet function following acute cerebral ischemia. Angiology (2009) 0.82
Abo-incompatible heart transplantation in infants: the Freeman Hospital experience. Transplantation (2004) 0.81
Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in patients with unprovoked VTE. Cochrane Database Syst Rev (2015) 0.78
Glycoprotein IIb/IIIa inhibitor associated severe thrombocytopenia in patients with coronary artery disease: Clinical course and outcomes. Platelets (2011) 0.77
Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm. Cochrane Database Syst Rev (2014) 0.76
Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE. Cochrane Database Syst Rev (2017) 0.75
Laparoscopic surgery for elective abdominal aortic aneurysm repair. Cochrane Database Syst Rev (2017) 0.75
Oral antiplatelet agents and bleeding risk in relation to major cardiovascular surgery. Curr Drug Saf (2006) 0.75
Outcome of ilio-popliteal grafting for peripheral arterial disease. Angiology (2009) 0.75
Endovascular versus conventional medical treatment for uncomplicated chronic type B aortic dissection. Cochrane Database Syst Rev (2012) 0.75
Vascular closure devices for femoral arterial puncture site haemostasis. Cochrane Database Syst Rev (2016) 0.75
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev (2017) 0.75
Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm. Cochrane Database Syst Rev (2017) 0.75
Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev (2017) 0.75
Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis. Cochrane Database Syst Rev (2016) 0.75
Surgical embolectomy is underused. BMJ (2013) 0.75